209 related articles for article (PubMed ID: 34733240)
1. Oestradiol Contributes to Differential Antitumour Effects of Adjuvant Zoledronic Acid Observed Between Pre- and Post-Menopausal Women.
Canuas-Landero VG; George CN; Lefley DV; Corness H; Muthana M; Wilson C; Ottewell PD
Front Endocrinol (Lausanne); 2021; 12():749428. PubMed ID: 34733240
[TBL] [Abstract][Full Text] [Related]
2. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
Ottewell PD; Wang N; Brown HK; Reeves KJ; Fowles CA; Croucher PI; Eaton CL; Holen I
Clin Cancer Res; 2014 Jun; 20(11):2922-32. PubMed ID: 24687923
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
[TBL] [Abstract][Full Text] [Related]
5. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
6. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
[TBL] [Abstract][Full Text] [Related]
7. Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions.
George CN; Canuas-Landero V; Theodoulou E; Muthana M; Wilson C; Ottewell P
J Bone Oncol; 2020 Dec; 25():100317. PubMed ID: 32995253
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
Ubellacker JM; Haider MT; DeCristo MJ; Allocca G; Brown NJ; Silver DP; Holen I; McAllister SS
Breast Cancer Res; 2017 Mar; 19(1):23. PubMed ID: 28264701
[TBL] [Abstract][Full Text] [Related]
11. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
[TBL] [Abstract][Full Text] [Related]
12. Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study.
Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Kann P
Breast Cancer Res Treat; 2014 Apr; 144(2):343-51. PubMed ID: 24519387
[TBL] [Abstract][Full Text] [Related]
13. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
Hiraga T; Ueda A; Tamura D; Hata K; Ikeda F; Williams PJ; Yoneda T
Int J Cancer; 2003 Oct; 106(6):973-9. PubMed ID: 12918079
[TBL] [Abstract][Full Text] [Related]
14. Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer - An AZURE (BIG 01/04) sub-study.
Wilson C; Hinsley S; Marshall H; Cameron D; Bell R; Dodwell D; Coleman RE
J Bone Oncol; 2017 Nov; 9():48-54. PubMed ID: 29234591
[TBL] [Abstract][Full Text] [Related]
15. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial.
Kyvernitakis I; Kann PH; Thomasius F; Hars O; Hadji P
Bone; 2018 Sep; 114():109-115. PubMed ID: 29908297
[TBL] [Abstract][Full Text] [Related]
16. Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).
Coleman RE; Collinson M; Gregory W; Marshall H; Bell R; Dodwell D; Keane M; Gil M; Barrett-Lee P; Ritchie D; Bowman A; Liversedge V; De Boer RH; Passos-Coelho JL; O'Reilly S; Bertelli G; Joffe J; Brown JE; Wilson C; Tercero JC; Jean-Mairet J; Gomis R; Cameron D
J Bone Oncol; 2018 Nov; 13():123-135. PubMed ID: 30591866
[TBL] [Abstract][Full Text] [Related]
17. Genetically-achieved disturbances to the expression levels of TNFSF11 receptors modulate the effects of zoledronic acid on growing mouse skeletons.
Vargas-Franco JW; Castaneda B; Gama A; Mueller CG; Heymann D; Rédini F; Lézot F
Biochem Pharmacol; 2019 Oct; 168():133-148. PubMed ID: 31260659
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid enhances bone-implant osseointegration more than alendronate and strontium ranelate in ovariectomized rats.
Chen B; Li Y; Yang X; Xu H; Xie D
Osteoporos Int; 2013 Jul; 24(7):2115-21. PubMed ID: 23389695
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model.
Hung TT; Chan J; Russell PJ; Power CA
PLoS One; 2011; 6(5):e19389. PubMed ID: 21603655
[TBL] [Abstract][Full Text] [Related]
20. The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.
Wilson C; Ottewell P; Coleman RE; Holen I
BMC Cancer; 2015 Feb; 15():55. PubMed ID: 25884855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
